GIinteractive11 | Case 1 - Gastric Cancer


A 67-year-old man with a prior h/o stent placement for coronary artery disease (CAD) presents with HER2-positive gastric cancer with extensive pulmonary metastases and experiences a major clinical response to FOLFOX/trastuzumab, but his ejection fraction (EF) decreases from 70 percent to 30 percent. He has no congestive heart failure symptoms, and treatment with trastuzumab is stopped.

If his EF normalized and the patient were to develop disease progression, would you likely use anti-HER2 treatment?

When testing HER2 in gastric cancer, it is acceptable to measure FISH alone without performing IHC.